The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients

Published Online:https://doi.org/10.1176/ajp.138.5.608

The authors decreased neuroleptic medication in 21 chronic schizophrenic patients in an attempt to minimize the risks of tardive dyskinesia. Level of psychopathology and severity of dyskinetic symptoms were monitored while the neuroleptic was gradually decreased over 3 months and then discontinued. Only 1 patient relapsed during drug decrease; however, 15 patients relapsed within 6 months after drug withdrawal. After relapse, medication was gradually increased. The doses needed to induce recovery were higher than those which had been sufficient to prevent relapse during gradual drug reduction. Dyskinetic symptoms were not significantly modified during drug reduction but increased significantly after drug discontinuation.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.